Tel.: 514-340-7593
samy.suissa@mcgill.ca
Samy Suissa, PhD
 
Director, Centre for Clinical Epidemiology, Lady Davis Institute
Professor, Departments of Epidemiology and Biostatistics and of Medicine, McGill University
 

Dr. Samy Suissa is Director of the Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, and a Distinguished James McGill Professor, Departments of Epidemiology and Biostatistics and of Medicine, McGill University. Dr. Suissa heads the Canadian Network for Observational Drug Effect Studies (CNODES) and the McGill Pharmacoepidemiology Research Unit. He was the founding Director of the Quebec Research Network on Medication Use, funded by the FRSQ.

Dr. Suissa has chaired and served on several review committees for the Fonds de la recherche en santé du Québec (FRSQ) and the Canadian Institutes of Health Research (CIHR), including chairing the FRSQ Chercheur-National awards committee. He served on several advisory boards, such as the External Advisory Board of PROTECT, the drug safety consortium formed by the European Innovative Medicines Initiative (IMI). He has served on the editorial boards of various scientific journals, including Diabetes Care, Gut, Pharmacoepidemiology and Drug Safety, the European Respiratory Journal, Lancet Respiratory Medicine, Multidisciplinary Respiratory Medicine, and the Journal of COPD. He is Co-head of the Research Methodology, Policy & General Interest for Faculty 1000 Medicine. He served as Associate Editor of the Journal of Disease Management and Health Outcomes, as well as Treatments in Respiratory Medicine. He was an elected member of the boards of directors of the International Society of Pharmacoepidemiology and of the Canadian Association for Pharmaceutical Therapeutics.

Dr. Suissa received Chercheur-Boursier awards from the FRSQ, a Senior Scientist award from the Medical Research Council of Canada (MRC) and the Distinguished Scientist award from Canadian Institute of Health Research (CIHR). He is a fellow of the Royal Society of Canada and of the Canadian Academy of Health Science, and was conferred the FC Donders Professor Award from the Universiteit Utrecht, Netherlands.


Major Research Activities

Dr. Suissa’s research is in the field of pharmacoepidemiology which involves studying the risks and benefits of medications in the real world setting of clinical practice. He specializes in the exploitation of large computerized health databases to rapidly evaluate these drug effects. He developed, and published extensively on new research methods that allow more rapid and accurate assessments of drug safety and effectiveness. He conducted studies of medications used for the treatment of several chronic diseases, including asthma and COPD, diabetes, cancer, cardiovascular and rheumatic diseases, and women’s health. He has lectured extensively throughout the world, and is the author of over 530 peer-reviewed research papers published in scientific journals.

Recent Publications
 
Suissa S, Ten Commandments for randomized trials of pharmacological therapy for COPD and other lung diseases.COPD. 2021;18(5):485-492.

Suissa S, Dell'Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Medicine 2018;6(11):855-862.

Suissa S, Drazen JM.Making sense of triple inhaled therapy for COPD.N Engl J Med. 2018;378(18):1723-1724.


Snapshot

Dr. Suissa is an internationally recognized scientist in the field of pharmacoepidemiology, and is frequently invited to speak at meetings and conferences.

Dr. Suissa has received several research scholar awards from FRSQ, MRC, and CIHR over the past 25 years, as well as the prestigious FC Donders Award from the Universiteit Utrecht.

Dr. Suissa has published extensive studies on the risks and benefits of commonly used medications for the treatment of several chronic diseases.

 
 
Important Links

 
Support research at the Lady Davis Institute - Jewish General Hospital